title: Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.
abstract: OBJECTIVE
  To examine the feasibility, efficacy, safety, and acceptability of medical abortion among rural and urban women up to 56 days of pregnancy in the Democratic People's Republic of Korea.
  
  
  METHODS
  A total of 199 women (rural n=95, urban n=104) recruited from 2 rural and 2 urban reproductive health clinics received 200mg of oral mifepristone followed 2 days later by 400 microg of sublingual misoprostol. The women's abortion status and satisfaction level were determined 2 weeks later.
  
  
  RESULTS
  Overall complete abortion occurred in 96.0% of the women; there was no statistically significant difference between the groups (rural 95.8%, 95% confidence interval [CI], 89.6-98.8; urban 96.2%, 95% CI, 90.4-98.9). The 2 groups reported similar adverse effects. In total, 90.5% of rural and 88.5% of urban participants were satisfied or very satisfied with the method.
  
  
  CONCLUSIONS
  The high efficacy and acceptability of medical abortion among rural and urban women suggest that medical abortion is a safe alternative to surgical abortion and can be scaled up to other reproductive health clinics in both rural and urban areas of the Democratic People's Republic of Korea, provided that there is appropriate training and supervision.
authors.affiliation: International Planned Parenthood Federation, East Southeast Asia and Oceania Regional Office (IPPF ESEAOR), 50450 Kuala Lumpur, Malaysia. ttran@ippf.org
authors.forename: Nguyen Toan
authors.initials: NT
authors.lastname: Tran
authors.forename: Myong Chon
authors.initials: MC
authors.lastname: Jang
authors.forename: Yong Su
authors.initials: YS
authors.lastname: Choe
authors.forename: Won Suk
authors.initials: WS
authors.lastname: Ko
authors.forename: Hae Suk
authors.initials: HS
authors.lastname: Pyo
authors.forename: Ok Suk
authors.initials: OS
authors.lastname: Kim
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000028:Abortion, Induced / Q000379:methods*; D000284:Administration, Oral; D000286:Administration, Sublingual; D000328:Adult; D056911:Democratic People's Republic of Korea; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D010865:Pilot Projects; D011247:Pregnancy; D019035:Rural Health Services; D019037:Urban Health Services
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone